- Home
- GDO vs ACHV Comparison
GDO vs ACHV Comparison
Compare GDO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDO
- ACHV
- Stock Information
- Founded
- GDO 2009
- ACHV N/A
- Country
- GDO United States
- ACHV Canada
- Employees
- GDO N/A
- ACHV N/A
- Industry
- GDO Finance Companies
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GDO Finance
- ACHV Health Care
- Exchange
- GDO Nasdaq
- ACHV Nasdaq
- Market Cap
- GDO 86.2M
- ACHV 92.6M
- IPO Year
- GDO N/A
- ACHV N/A
- Fundamental
- Price
- GDO $11.46
- ACHV $2.70
- Analyst Decision
- GDO
- ACHV Strong Buy
- Analyst Count
- GDO 0
- ACHV 4
- Target Price
- GDO N/A
- ACHV $15.75
- AVG Volume (30 Days)
- GDO 39.4K
- ACHV 162.2K
- Earning Date
- GDO 01-01-0001
- ACHV 03-11-2025
- Dividend Yield
- GDO 9.81%
- ACHV N/A
- EPS Growth
- GDO N/A
- ACHV N/A
- EPS
- GDO N/A
- ACHV N/A
- Revenue
- GDO N/A
- ACHV N/A
- Revenue This Year
- GDO N/A
- ACHV N/A
- Revenue Next Year
- GDO N/A
- ACHV N/A
- P/E Ratio
- GDO N/A
- ACHV N/A
- Revenue Growth
- GDO N/A
- ACHV N/A
- 52 Week Low
- GDO $11.21
- ACHV $2.51
- 52 Week High
- GDO $13.04
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- GDO 46.01
- ACHV 41.28
- Support Level
- GDO $11.37
- ACHV $2.70
- Resistance Level
- GDO $11.49
- ACHV $2.99
- Average True Range (ATR)
- GDO 0.09
- ACHV 0.20
- MACD
- GDO -0.02
- ACHV 0.01
- Stochastic Oscillator
- GDO 16.56
- ACHV 34.55
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.